Mitchell S. Kapoor
Stock Analyst at HC Wainwright & Co.
(3.71)
# 847
Out of 4,996 analysts
31
Total ratings
58.62%
Success rate
7.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mitchell S. Kapoor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Buy | $80 | $61.67 | +29.72% | 1 | Sep 23, 2025 | |
| IONS Ionis Pharmaceuticals | Reiterates: Buy | $95 | $64.09 | +48.23% | 3 | Sep 23, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $85 | $73.75 | +15.25% | 1 | Sep 22, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $25 → $30 | $16.31 | +83.94% | 2 | Sep 19, 2025 | |
| AVTX Avalo Therapeutics | Maintains: Buy | $15 → $25 | $10.80 | +131.48% | 1 | Sep 17, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $50 | $20.95 | +138.66% | 5 | Sep 16, 2025 | |
| TIL Instil Bio | Reiterates: Buy | $125 | $16.93 | +638.33% | 3 | Sep 11, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Neutral | $60 | $53.85 | +11.42% | 1 | Sep 8, 2025 | |
| EDIT Editas Medicine | Reiterates: Buy | $5 | $3.24 | +54.32% | 2 | Sep 5, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Buy | $5 → $10 | $6.10 | +63.93% | 1 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $12.43 | +101.13% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sell | $5 | $18.36 | -72.77% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $12.97 | +131.30% | 1 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.29 | +205.68% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $2.41 | -17.01% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $15.20 | +196.05% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $9 | $6.77 | +32.94% | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $4.05 | +245.68% | 1 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $40.66 | +121.35% | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.14 | +250.88% | 1 | Aug 11, 2025 |
CRISPR Therapeutics AG
Sep 23, 2025
Reiterates: Buy
Price Target: $80
Current: $61.67
Upside: +29.72%
Ionis Pharmaceuticals
Sep 23, 2025
Reiterates: Buy
Price Target: $95
Current: $64.09
Upside: +48.23%
Halozyme Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $75 → $85
Current: $73.75
Upside: +15.25%
Intellia Therapeutics
Sep 19, 2025
Maintains: Buy
Price Target: $25 → $30
Current: $16.31
Upside: +83.94%
Avalo Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $10.80
Upside: +131.48%
Summit Therapeutics
Sep 16, 2025
Reiterates: Buy
Price Target: $50
Current: $20.95
Upside: +138.66%
Instil Bio
Sep 11, 2025
Reiterates: Buy
Price Target: $125
Current: $16.93
Upside: +638.33%
BioMarin Pharmaceutical
Sep 8, 2025
Initiates: Neutral
Price Target: $60
Current: $53.85
Upside: +11.42%
Editas Medicine
Sep 5, 2025
Reiterates: Buy
Price Target: $5
Current: $3.24
Upside: +54.32%
Kyverna Therapeutics
Aug 29, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $6.10
Upside: +63.93%
Aug 27, 2025
Reiterates: Buy
Price Target: $25
Current: $12.43
Upside: +101.13%
Aug 25, 2025
Reiterates: Sell
Price Target: $5
Current: $18.36
Upside: -72.77%
Aug 22, 2025
Reiterates: Buy
Price Target: $30
Current: $12.97
Upside: +131.30%
Aug 19, 2025
Reiterates: Buy
Price Target: $7
Current: $2.29
Upside: +205.68%
Aug 19, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $2.41
Upside: -17.01%
Aug 18, 2025
Reiterates: Buy
Price Target: $45
Current: $15.20
Upside: +196.05%
Aug 15, 2025
Maintains: Buy
Price Target: $15 → $9
Current: $6.77
Upside: +32.94%
Aug 14, 2025
Reiterates: Buy
Price Target: $14
Current: $4.05
Upside: +245.68%
Aug 13, 2025
Maintains: Buy
Price Target: $100 → $90
Current: $40.66
Upside: +121.35%
Aug 11, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.14
Upside: +250.88%